Nothing Special   »   [go: up one dir, main page]

EA201790983A1 - Синтез копанлисиба и его дигидрохлорида - Google Patents

Синтез копанлисиба и его дигидрохлорида

Info

Publication number
EA201790983A1
EA201790983A1 EA201790983A EA201790983A EA201790983A1 EA 201790983 A1 EA201790983 A1 EA 201790983A1 EA 201790983 A EA201790983 A EA 201790983A EA 201790983 A EA201790983 A EA 201790983A EA 201790983 A1 EA201790983 A1 EA 201790983A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dihydrochloride
copanlisib
kopanlisib
synthesis
hydrates
Prior art date
Application number
EA201790983A
Other languages
English (en)
Other versions
EA035558B1 (ru
Inventor
Ян-Георг Петерс
Филипп Рубенбауэр
Даниэль Гётц
Даня Гроссбах
Франц-Йозеф Маис
Хайко Ширмер
Йюрген Штиль
Кай Ловис
Андреас Лендер
Мартин Зайфрид
Теодор Цвайфель
Морус Марти
Гюнтер Вайнгертнер
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201790983A1 publication Critical patent/EA201790983A1/ru
Publication of EA035558B1 publication Critical patent/EA035558B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к новому способу получения копанлисиба, дигидрохлорида копанлисиба, или гидратов дигидрохлорида копанлисиба, к новым промежуточным соединениям и к применению указанных новых промежуточных соединений для приготовления указанного копанлисиба, дигидрохлорида копанлисиба, или гидратов дигидрохлорида копанлисиба. Настоящее изобретение также относится к гидратам дигидрохлорида копанлисиба в качестве соединений.
EA201790983A 2014-11-07 2015-11-05 Синтез копанлисиба и его дигидрохлорида EA035558B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192203.9A EP3018127A1 (en) 2014-11-07 2014-11-07 Synthesis of copanlisib and its dihydrochloride salt
PCT/EP2015/075789 WO2016071435A2 (en) 2014-11-07 2015-11-05 Synthesis of copanlisib and its dihydrochloride salt

Publications (2)

Publication Number Publication Date
EA201790983A1 true EA201790983A1 (ru) 2017-10-31
EA035558B1 EA035558B1 (ru) 2020-07-07

Family

ID=51866061

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790983A EA035558B1 (ru) 2014-11-07 2015-11-05 Синтез копанлисиба и его дигидрохлорида

Country Status (47)

Country Link
US (1) US10494372B2 (ru)
EP (2) EP3018127A1 (ru)
JP (1) JP6691115B2 (ru)
KR (1) KR102566834B1 (ru)
CN (1) CN107278204B (ru)
AR (1) AR102570A1 (ru)
AU (1) AU2015341788B2 (ru)
BR (1) BR112017009470B1 (ru)
CA (1) CA2966800C (ru)
CL (1) CL2017001131A1 (ru)
CO (1) CO2017004532A2 (ru)
CR (1) CR20170184A (ru)
CU (1) CU24489B1 (ru)
CY (1) CY1121602T1 (ru)
DK (1) DK3215493T3 (ru)
DO (1) DOP2017000112A (ru)
EA (1) EA035558B1 (ru)
EC (1) ECSP17027755A (ru)
ES (1) ES2721778T3 (ru)
HK (1) HK1245774A1 (ru)
HR (1) HRP20190720T1 (ru)
HU (1) HUE042866T2 (ru)
IL (1) IL251874A0 (ru)
JO (1) JO3644B1 (ru)
LT (1) LT3215493T (ru)
MA (1) MA40895B1 (ru)
ME (1) ME03358B (ru)
MX (1) MX366904B (ru)
MY (1) MY189852A (ru)
NI (1) NI201700054A (ru)
NZ (1) NZ731287A (ru)
PE (1) PE20170897A1 (ru)
PH (1) PH12017500833A1 (ru)
PL (1) PL3215493T3 (ru)
PT (1) PT3215493T (ru)
RS (1) RS58579B1 (ru)
SA (1) SA517381462B1 (ru)
SG (1) SG11201703702RA (ru)
SI (1) SI3215493T1 (ru)
SV (1) SV2017005433A (ru)
TN (1) TN2017000179A1 (ru)
TR (1) TR201905217T4 (ru)
TW (1) TWI697495B (ru)
UA (1) UA122398C2 (ru)
UY (1) UY36392A (ru)
WO (1) WO2016071435A2 (ru)
ZA (1) ZA201703867B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
TN2015000452A1 (en) 2013-04-08 2017-04-06 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
WO2016142312A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
CN108884098B (zh) 2016-03-08 2021-09-14 拜耳制药股份公司 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
JP2019532922A (ja) 2016-09-23 2019-11-14 バイエル ファーマ アクチエンゲゼルシャフト Pi3k−阻害剤の組み合わせ
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
EP3645005A1 (en) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combination of a pi3k-inhibitor with an androgen receptor antagonist
RS64316B1 (sr) 2017-09-08 2023-08-31 Bayer Pharma AG Formulacije kopanlisiba
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
WO2023139125A1 (en) 2022-01-18 2023-07-27 Synthon B.V. Improved process for preparation of copanlisib
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003580A (en) 1910-08-10 1911-09-19 Remington Typewriter Co Type-writing machine.
US6221877B1 (en) * 2000-04-12 2001-04-24 Regents Of The University Of California Substituted 4-phthalimidocarboxanilides as inhibitors of purine salvage phosphoribosyltransferases
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
TW565582B (en) * 2001-04-13 2003-12-11 Kaneka Corp Diamine, acid dianhydride, and reactive group containing polyimide composition prepared therefrom and preparing them
JP4445751B2 (ja) * 2001-08-15 2010-04-07 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 無脊椎有害生物を防除するためのo−複素環式置換アリールアミド
SI1549652T1 (sl) 2002-09-30 2009-04-30 Bayer Healthcare Ag Kondenzirani azolpirimidinski derivati
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
US8859572B2 (en) 2008-01-14 2014-10-14 Bayer Intellectual Property Gmbh Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
TN2015000452A1 (en) 2013-04-08 2017-04-06 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
US10117874B2 (en) 2013-12-03 2018-11-06 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
BR112017019190A2 (pt) 2015-03-09 2018-04-24 Bayer Healthcare Pharmaceuticals Inc uso de 2,3-di-hidroimidazo[1,2-c]quinazolinas substituídas
WO2016142312A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
KR20180104129A (ko) 2016-02-01 2018-09-19 바이엘 파마 악티엔게젤샤프트 코판리십 바이오마커
SG10202007262PA (en) 2016-02-01 2020-09-29 Bayer Pharma AG Copanlisib biomarkers
CN108884098B (zh) 2016-03-08 2021-09-14 拜耳制药股份公司 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
JP2019532922A (ja) 2016-09-23 2019-11-14 バイエル ファーマ アクチエンゲゼルシャフト Pi3k−阻害剤の組み合わせ

Also Published As

Publication number Publication date
PE20170897A1 (es) 2017-07-12
US10494372B2 (en) 2019-12-03
MY189852A (en) 2022-03-14
CA2966800C (en) 2023-02-21
MX2017005893A (es) 2017-06-30
EP3215493B1 (en) 2019-01-23
AU2015341788B2 (en) 2020-01-16
AU2015341788A1 (en) 2017-05-18
LT3215493T (lt) 2019-04-25
CY1121602T1 (el) 2020-05-29
SG11201703702RA (en) 2017-06-29
MX366904B (es) 2019-07-30
BR112017009470A2 (pt) 2018-01-02
DOP2017000112A (es) 2017-06-15
MA40895A (fr) 2017-09-13
ME03358B (me) 2019-10-20
SV2017005433A (es) 2018-04-30
CO2017004532A2 (es) 2017-07-19
ES2721778T3 (es) 2019-08-05
CU24489B1 (es) 2020-12-17
SI3215493T1 (sl) 2019-05-31
CU20170061A7 (es) 2017-10-05
UY36392A (es) 2016-06-30
PL3215493T3 (pl) 2019-07-31
CL2017001131A1 (es) 2018-01-19
TWI697495B (zh) 2020-07-01
SA517381462B1 (ar) 2021-01-25
AR102570A1 (es) 2017-03-08
UA122398C2 (uk) 2020-11-10
TR201905217T4 (tr) 2019-05-21
BR112017009470B1 (pt) 2022-11-01
JO3644B1 (ar) 2020-08-27
KR20170082563A (ko) 2017-07-14
IL251874A0 (en) 2017-06-29
RS58579B1 (sr) 2019-05-31
EA035558B1 (ru) 2020-07-07
EP3215493A2 (en) 2017-09-13
PH12017500833A1 (en) 2017-10-18
EP3018127A1 (en) 2016-05-11
HUE042866T2 (hu) 2019-07-29
MA40895B1 (fr) 2019-07-31
CN107278204B (zh) 2019-12-17
HRP20190720T1 (hr) 2019-06-14
TW201625634A (zh) 2016-07-16
CA2966800A1 (en) 2016-05-12
ZA201703867B (en) 2019-07-31
PT3215493T (pt) 2019-05-21
WO2016071435A2 (en) 2016-05-12
NZ731287A (en) 2023-01-27
TN2017000179A1 (en) 2018-10-19
HK1245774A1 (zh) 2018-08-31
KR102566834B1 (ko) 2023-08-16
DK3215493T3 (da) 2019-05-06
NI201700054A (es) 2017-07-17
WO2016071435A3 (en) 2016-06-30
JP6691115B2 (ja) 2020-04-28
JP2017534631A (ja) 2017-11-24
ECSP17027755A (es) 2017-06-30
CR20170184A (es) 2017-06-20
US20180282337A1 (en) 2018-10-04
CN107278204A (zh) 2017-10-20

Similar Documents

Publication Publication Date Title
EA201790983A1 (ru) Синтез копанлисиба и его дигидрохлорида
EA201692193A1 (ru) Способы получения ингибитора jak1 и его новых форм
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
EA201892430A1 (ru) Синтез индазолов
EA201691649A1 (ru) Способ получения противогрибковых соединений
EA201691648A1 (ru) Способ получения противогрибковых соединений
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
MX2018007219A (es) Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol.
BR112016027455A2 (pt) moduladores ppar
EA201791645A1 (ru) Новые соли и полиморфы scy-078
EA201790428A1 (ru) Синтез энт-прогестерона и его промежуточных соединений
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
IN2014MU00070A (ru)
IN2014MU00069A (ru)
IN2013MU01524A (ru)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KG TJ TM